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ABSTRACT
We have developed an approach that enables non-
radioactive, ultrasensitive (attamole sensitivity) site-
specific protein–protein photocrosslinking, and we
have applied the approach to the analysis of inter-
actions of a-helix 2 (H2) of human TATA-element
binding protein (TBP) with general transcription
factor TFIIA and transcriptional repressor NC2. We
have found that TBP H2 can be crosslinked to TFIIA
in the TFIIA–TBP–DNA complex and in higher order
transcription–initiation complexes, and we have
mapped the crosslink to the ‘connector’ region of
the TFIIA a/b subunit (TFIIAa/b). We further have
found that TBP H2 can be crosslinked to NC2 in
the NC2–TBP–DNA complex, and we have mapped
the crosslink to the C-terminal ‘tail’ of the NC2
a-subunit (NC2a). Interactions of TBP H2 with the
TFIIAa/b connector and the NC2a C-terminal tail
were not observed in crystal structures of TFIIA–
TBP–DNA and NC2–TBP–DNA complexes, since
relevant segments of TFIIA and NC2 were not pres-
ent in truncated TFIIA and NC2 derivatives used
for crystallization. We propose that interactions
of TBP H2 with the TFIIAa/b connector and the
NC2a C-terminal tail provide an explanation for
genetic results suggesting importance of TBP H2
in TBP–TFIIA interactions and TBP–NC2 inter-
actions, and provide an explanation—steric
exclusion—for competition between TFIIA and NC2.
INTRODUCTION
This work provides evidence for interactions of a-helix 2
(H2) of human TATA-element binding protein (TBP)
with the human general transcription factor TFIIA and
with the human transcriptional repressor NC2.
TBP is the critical functional subunit of the eukaryotic
general transcription factor TFIID (1–4). In transcription
initiation at a eukaryotic protein-encoding gene, TBP
binds to the TATA element, bends the TATA element
and nucleates assembly of general transcription factors
and RNA polymerase II (RNAPII) to yield a transcription
initiation complex. Human TBP has a molecular mass of
37kDa and consists of a nonconserved, unstructured
N-terminal domain (TBPn) and a conserved, structured
C-terminal domain (TBPc). Human TBPc contains all
determinants required for DNA binding, DNA bending
and transcription–initiation-complex assembly.
The eukaryotic general transcription factor TFIIA facil-
itates formation of stable TBP–DNA complexes and
higher order transcription–initiation complexes (1–5).
TFIIA functions by binding to TBP–DNA complexes
and higher order transcription–initiation complexes,
making protein–protein interactions with TBP and
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the TATA element. TFIIA is able to mediate responses to
transcriptional activators; in this role, TFIIA is recruited
by transcriptional activators to speciﬁc target promoters,
where it facilitates formation of stable TBP–DNA and
higher order transcription–initiation complexes. Human
TFIIA has a molecular mass of 53kDa and consists of
one TFIIAa/b subunit (or its proteolytic-cleavage pro-
ducts, TFIIAa and TFIIAb) and one TFIIAg subunit.
The eukaryotic transcriptional repressor NC2 (also
known as Drap1/Dr1) inhibits formation of transcrip-
tion–initiation complexes (6,7). Human NC2 functions by
inhibiting two sets of interactions: (i) interactions between
the general transcription factor TFIIA and TBP and
(ii) interactions between the general transcription factor
TFIIB and TBP. Human NC2 has a molecular mass of
42kDa and consists of one NC2a subunit (also known as
Drap1) and one NC2b subunit (also known as Dr1).
Full structural descriptions of TFIIA–TBP interactions
and of NC2–TBP interactions have remained elusive, and,
as a result, an understanding of the structural basis of
competition between TFIIA and NC2 has remained
elusive.
Four crystal structures of TFIIA–TBP–DNA complexes
have been reported (8–10). One set of expected, genetically
deﬁned, TFIIA–TBP interactions, involving TBP b-strand
2 (11), is observed in the four crystal structures (8–10).
However, a second set of expected, genetically and spectro-
scopically deﬁned, TFIIA–TBP interactions, involving
TBP a-helix 2 (H2; 12–17), is not observed—or is observed
only equivocally and in part—in the four crystal structures
(8–10). A large segment of TFIIA, comprising >100 amino
acids in the ‘connector’ segment of the TFIIAa/b subunit
of TFIIA, was omitted from the polypeptides used for
crystallization for the four crystal structures. This omission
may account for the failure to observe the second set of
expected TFIIA–TBP interactions.
One crystal structure of an NC2–TBP–DNA complex
has been reported (7). One set of expected, genetically
deﬁned, NC2–TBP interactions, involving the loop
between TBP a-helix 20 and b-strands 20–40 (16), is
observed in the crystal structure (7). However, a second
set of expected, genetically deﬁned, NC2–TBP interac-
tions, involving TBP H2 (18), is not observed in the crystal
structure (7). The crystal structure provides a clear basis
for observed competition between NC2 and TFIIB (with
overlap, and steric clash, between observed positions of
residues of NC2 that interact with TBP and observed posi-
tions of residues of TFIIB that interact with TBP).
However, the crystal structure does not provide a clear
basis for observed competition between NC2 and TFIIA
(with minimal overlap, and minimal steric incompatibility,
between observed positions of residues of NC2 that inter-
act with TBP and residues of TFIIA that interact with
TBP). A large segment of NC2a, comprising the C-term-
inal ‘tail’ of NC2a, was omitted from the polypeptide used
for crystallization. This omission may account for the fail-
ure to observe the second set of expected NC2–TBP inter-
actions and for the failure to provide a clear basis for
competition between NC2 and TFIIA.
In this work, to provide a more complete description
of TFIIA–TBP and NC2–TBP interactions—and, in parti-
cular, to deﬁne possible interactions involving TBP H2 and
possible interactions involving TFIIA and NC2 determi-
nants omitted from polypeptides used for crystalliza-
tion—we have performed site-speciﬁc protein–protein
photocrosslinking (19,20). To facilitate the work and to
enable the extension of the work to higher order transcrip-
tion-initiation complexes that can be produced in only lim-
ited quantities, we have developed novel reagents and
procedures for nonradioactive, ultrasensitive (attamole
sensitivity) site-speciﬁc protein–protein photocrosslinking.
EXPERIMENTAL PROCEDURES
(2-((N-biotinyl-2-aminoethyl)carbamoyl)-2’-
tritylamino-ethylthio)-triphenylmethane (I)
Biotin ethylenediamine HBr (Invitrogen, Inc., Carlsbad,
CA, USA; 100mg; 0.27mmol) was added to a
solution of N-(N-trityl-S-trityl-L-cysteinyloxy)succinimide
(Novabiochem, Inc., Gibbstown, NJ, USA; 190mg;
0.24mmol,) in 10ml anhydrous dimethylformamide and
80ml triethylamine, and the sample was stirred overnight
at room temperature under argon. The sample was evapo-
rated to a viscous oil, redissolved in 10ml chloroform,
extracted with 10ml 5% sodium bicarbonate, extracted
with 10ml brine, dried over anhydrous sodium sulfate
and evaporated to a foamy white solid. Yield: 186mg
(0.21mmol; 89% yield). (M+H
+): calculated, 874;
found, 874.
(2-((N-biotinyl-2-aminoethyl)carbamoyl)-2’-
(4-azidosalicylamido)-ethylthio)-triphenylmethane (II)
Triﬂuoroacetic acid (Aldrich Inc., St. Louis, MO, USA;
200ml) was added to a solution of I (168mg; 0.192mmol)
in 3ml chloroform. The resulting yellow solution was
mixed well and was allowed to react for 10min.
Methanol was then added until the yellow color disap-
peared. The sample was evaporated to an oil and partly
puriﬁed by silica ﬂash chromatography (240–400 mesh;
10–20% methanol in chloroform) to aﬀord (2-((N-bioti-
nyl-2-aminoethyl)carbamoyl)-20-amino-ethylthio)-triphe-
nylmethane. Yield: 150mg white powder (0.24mmol;
>100% crude yield). (M+H
+): calculated, 632; found,
632. The resulting material (150mg; 0.24mmol; dissolved
in 3ml DMF and 54ml triethylamine) was added to N-
hydroxysuccinimidyl-4-azidosalicylic acid (Aldrich, Inc.;
50mg; 0.018mmol; dissolved in 1ml dimethylformamide)
and the sample was stirred overnight at room temperature
under argon. Methanol (1ml) was added to quench the
reaction, and the sample was evaporated to a viscous oil,
redissolved in 10ml chloroform, extracted with 10ml 5%
sodium bicarbonate, extracted with 10ml brine, dried over
anhydrous sodium sulfate and concentrated to a viscous
oil. The product was puriﬁed by silica ﬂash chromatogra-
phy (10% methanol in chloroform). Yield: 76mg
(0.096mmol; 53% yield). (M+H
+): calculated, 793;
found, 793.
6144 Nucleic Acids Research, 2008, Vol. 36, No. 19S-(2-((N-biotinyl-2-aminoethyl)carbamoyl)-2’-
(4-azidosalicylamido)-ethylthio)-2-thiopyridine(III;B-AET)
Triﬂuoroacetic acid (Aldrich, Inc.; 1ml) and triethylsilane
(Aldrich, Inc.; 100ml; 0.626mmol) were added to a solu-
tion of II (60mg; 0.075mmol) in 1ml dichloromethane.
The yellow solution was mixed well for 5min and then
evaporated to a white powder. The sample was triturated
with 2ml cold methanol, redissolved in chloroform and
puriﬁed by ﬂash chromatography (15% MeOH in
CHCl3.) to aﬀord 2-((N-biotinyl-2-aminoethyl)carba-
moyl)-20-(4-azidosalicylamido)-ethyl sulﬁde. Yield: 33mg
white solid (0.061mmol; 81% yield). (M+H
+): calcu-
lated, 551; found, 551. The resulting material (28mg;
0.05mmol; dissolved in 2ml methanol and 400ml acetic
acid) was added, in 200ml aliquots over 20min, to
2,20-dithiodipyridine (Aldrich, Inc.; 55mg; 0.25mmol; dis-
solved in 2ml methanol and 80ml acetic acid). The sample
was evaporated to a yellow oil, triturated with diethyl
ether, redissolved in chloroform and puriﬁed by repeated
cycles of preparative thin-layer chromatography on
silica gel (Analtech, Inc., Newark, DE, USA; 1000mm;
10% methanol in chloroform). (Repeated cycles of pre-
parative thin-layer chromatography were needed to elim-
inate all traces of 2-thiopyridine.) Yield: 8mg white solid
(0.012mmol; 24% yield). (M+H
+): calculated, 661;
found, 661.
(2-((N-biotinyl-11-amino-3,6,9-trioxaundecanyl)-
carbamoyl)-2’-tritylamino-ethylthio)-triphenylmethane (IV)
(+)-Biotinyl-3,6,9-trioxaundecanediamine (Pierce, Inc.,
Rockford, IL, USA; 50mg; 0.12mmol) in 300ml
anhydrous dimethylformamide was added to a
solution of N-(N-trityl-S-trityl-L-cysteinyloxy)succinimide
(Novabiochem, Inc.; 84mg; 0.12mmol) in 300ml anhy-
drous dimethylformamide and 20ml triethylamine, and
the sample was stirred overnight at room temperature
under argon. The sample was evaporated to a viscous
oil, redissolved in 4ml chloroform, extracted with 4ml
5% sodium bicarbonate, extracted with 4ml brine, dried
over anhydrous sodium sulfate and evaporated to a
creamy white solid. Yield: 114mg (0.115mmol; 96%
yield). (M+H
+): calculated, 993; found, 993.
(2-((N-biotinyl-11-amino-3,6,9-trioxaundecanyl)-
carbamoyl)-2’-(4-azidosalicylamido)-ethylthio)-
triphenylmethane (V)
Triﬂuoroacetic acid (Aldrich, Inc.; 200ml) was added to
a solution of IV (90mg; 0.091mmol) in 3ml chloroform.
The resulting yellow solution was mixed well and was
allowed to react for 10min. Methanol then was added
until the yellow color disappeared. The sample was
evaporated to an oil and puriﬁed by silica ﬂash chromato-
graphy (240–400 mesh; 10% methanol in chloroform)
to aﬀord (2-((N-biotinyl-11-amino-3,6,9-trioxaundecanyl)
carbamoyl)-20-amino-ethylthio)-triphenylmethane. Yield:
51mg white solid (0.068mmol; 75% yield). (M+H
+):
calculated, 750; found, 750. The resulting
material (51mg; 0.068mmol; dissolved in 2ml dimethyl-
formamide and 20ml triethylamine) was added to
N-hydroxysuccinimidyl-4-azidosalicylic acid (Aldrich,
Inc.; 20mg; 0.072mmol; dissolved in 1ml dimethylforma-
mide), and the sample was stirred overnight at room tem-
perature under argon. Methanol (1ml) was added to
quench the reaction, and the sample was then evaporated
to a viscous oil, redissolved in 5ml chloroform, extracted
with 5ml 5% sodium bicarbonate, extracted with 5ml
brine, dried over anhydrous sodium sulfate, concentrated
to a viscous oil and puriﬁed by silica ﬂash chromatogra-
phy (10% methanol in chloroform). Yield: 27mg
(0.030mmol; 42% yield). (M+H
+): calculated, 911;
found, 911.
S-(2-((N-biotinyl-11-amino-3,6,9-trioxaundecanyl)carba-
moyl)-2’-(4-azidosalicylamido)-ethylthio)-2-thiopyridine
(VI; B-TEG-AET)
Triﬂuoroacetic acid (Aldrich, Inc.; 500ml) and triethylsi-
lane (Aldrich, Inc.; 50ml; 0.318mmol) were added to a
solution of V (27mg; 0.030mmol) in 0.5ml dichloro-
methane. The yellow solution was mixed well for 10min
and then evaporated to a white powder. The sample
was triturated with 1ml cold methanol, redissolved in
chloroform and puriﬁed by ﬂash chromatography
(10% methanol in chloroform.) to aﬀord (2-((N-biotinyl-
11-amino-3,6,9-trioxaundecanyl)carbamoyl)-20-(4-azido-
salicylamido)-ethyl sulﬁde. Yield: 16.4mg white solid
(0.025mmol; 83% yield). (M+H
+): calculated, 669;
found, 669. The resulting material (16mg, 0.025mmol;
dissolved in 1ml methanol and 200ml acetic acid) was
added, in 50ml aliquots over 20min, to 2,20-dithiodipyri-
dine (Aldrich, Inc.; 30mg; 0.136mmol; dissolved in 1ml
methanol and 50ml acetic acid). The sample was evapo-
rated to a yellow oil, triturated with diethyl ether, redis-
solved in chloroform and puriﬁed by repeated cycles of
preparative thin-layer chromatography in silica gel
(Analtech, Inc.; 250mm; 10% methanol in chloroform).
Yield: 8.5mg white solid (0.011mmol; 44% yield).
(M+H
+): calculated, 778; found, 778.
DNA fragments
DNA fragment AdMLP( 50/ 16) contains positions  50
to  16 of the adenovirus major late promoter. DNA frag-
ment AdMLP( 50/ 16)-NH2 contains positions  50 to
 16 of the adenovirus major late promoter and also con-
tains a bottom-strand 50-terminal C6 amino link. DNA
fragments were prepared by total synthesis.
DNA agarose
AdMLP( 50/ 16)-agarose was prepared by reaction of
DNA fragment AdMLP( 50/ 16)-NH2 (60pmol or
2nmol in 0.1M sodium carbonate, pH 8.6) with
Aﬃprep15 Agarose (BioRad, Inc., Hercules, CA, USA;
1ml) per instructions of the manufacturer, was washed
with TE (20mM Tris–HCl, pH 8.0 and 1mM EDTA)
and was stored in TE at 48C. The incorporation eﬃciency
was  50% (i.e.  30pmol or  1nmol DNA fragment
incorporated per milliliter agarose).
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Plasmid pHTT7f1-NH-TBPc encodes N-terminally hexa-
histidine-tagged human TBPc under control of the bacter-
iophage gene 10 promoter and the lac operator (15).
Derivatives of plasmid pHTT7f1-NH-TBPc encoding
N-terminally hexahistidine-tagged [Thr176]TBPc and
[Thr176;Cys236]TBPc were constructed using site-directed
mutagenesis (21). TBPc derivatives were overproduced in
transformants of Escherichia coli strain BL21(DE3)
(Novagen, Inc., Madison, WI, USA); puriﬁed under
native conditions by metal-ion aﬃnity chromatography
on Ni
2+-NTA-agarose [Qiagen, Inc., Valencia, CA,
USA; loading in buﬀer A (20mM Tris–HCl, pH 7.9,
500mM NaCl and 1mM b-mercaptoethanol) containing
5mM imidazole; washing with buﬀer A containing 5mM
imidazole and buﬀer A containing 50mM imidazole; and
elution with buﬀer A containing 150mM imidazole];
desalted into buﬀer B (20mM Tris–HCl, pH 7.9,
500mM KCl, 0.1mM EDTA and 15% glycerol) on Bio-
Gel P-6DG (BioRad, Inc.); concentrated using collodion
membranes (Schleicher & Schuell, Inc., Dassel, Germany;
10K MWCO); and stored in aliquots at  808C. Typically,
the yield was 2–3mg TBPc derivative per liter of bacterial
culture. Quantitation of solvent-accessible cysteine was
performed by a modiﬁcation of the procedure of Ref.
(22). Reactions contained (500ml): 2mM TBPc derivative,
0.1mM 5,50-dithiobis(2-nitrobenzoate) (Aldrich, Inc.),
20mM Tris–HCl, pH 8.0, 200mM KCl and 5% glycerol.
Formation of 5-thio-2-nitrobenzoate anion was estimated
from absorbance at 412nm after reaction for 15min
("412=13 600M
 1cm
 1).
Labeled TBPcderivatives
Reaction mixtures contained (400ml): 300mM TBPc deri-
vative [subjected to solid-phase reduction on Reduce-Imm
(Pierce, Inc.) per instructions of the manufacturer imme-
diately before use], 300mM B-AET or B-TEG-AET,
100mM sodium phosphate, pH 8.0, 1mM EDTA and
5% dimethylsulfoxide. Following 20min at 228C samples
were applied to a NAP-10 desalting column (GE
Healthcare Life Sciences, Inc., Piscataway, NJ, USA)
pre-equilibrated in buﬀer B and were eluted in buﬀer B.
Samples were concentrated and dialyzed against buﬀer C
(20mM Tris–HCl, pH 7.9, 100mM KCl, 0.1mM EDTA
and 15% glycerol) using collodion membranes (Schleicher
& Schuell, Inc.; 10K MWCO) and were stored in aliquots
at  808C. Labeling eﬃciencies and labeling speciﬁcities
were determined spectrophotometrically (using
"278=10,887M
 1cm
 1 and "330=0M
 1cm
 1 for the
protein; and using "278=2000M
 1cm
 1,
"330=4576M
 1cm
 1 for the probe). Labeling eﬃciencies
also were determined by quantitation of solvent-accessible
cysteine (methods as in preceding paragraph).
TFIIA derivatives
Plasmids pQTFIIA-ab and pQTFIIA-g encode
N-terminally hexahistidine-tagged human TFIIAa/b and
N-terminally hexahistidine-tagged human TFIIAg
under control of a bacteriophage T5 promoter and lac
operator (23). Derivatives of plasmid pQTFIIA-ab encod-
ing N-terminally hexahistidine-tagged [Ala337]TFIIAa/b,
[Cys61;Ala337]TFIIAa/b, [Cys80;Ala337]TFIIAa/b,
[Cys95;Ala337]TFIIAa/b, [Cys110;Ala337]TFIIAa/b,
[Cys135;Ala337]TFIIAa/b and [Cys214;Ala337]TFIIAa/b
were constructed using site-directed mutagenesis (21).
TFIIAa/b derivatives and TFIIg derivatives were overpro-
duced in transformants of E. coli strain M15(pREP4)
(Invitrogen, Inc.) TFIIAa/b derivatives and TFIIg deriva-
tives were puriﬁed, and TFIIA derivatives were reconsti-
tuted, by the procedures of Ref. (23). The resulting TFIIA
derivativesweredialyzedagainstbuﬀerD(25mMTris–HCl,
pH 7.9, 500mM KCl, 0.1mM EDTA and 10% glycerol);
concentrated using collodion membranes (Schleicher &
Schuell,Inc.;25KMWCO);furtherpuriﬁedbygelﬁltration
on Superdex 200 10/30 (GE Healthcare, Inc.); desalted into
buﬀer E (25mM Tris–HCl, pH 7.9, 100mM KCl, 0.1mM
EDTAand10%glycerol)onBio-GelP-6DG(BioRad,Inc.)
andstored in aliquots at 808C.
NC2 derivatives
Plasmids pET15b-DRAP1 and pET-NH-DR1 encode
N-terminally hexahistidine-tagged human NC2a and
N-terminally hexahistidine-tagged human NC2b under
control of the bacteriophage gene 10 promoter and the
lac operator (24,25). A derivative of plasmid pET15b-
DRAP1 encoding N-terminally hexahistidine-tagged
[Ser54]NC2a was constructed using site-directed muta-
genesis (21). NC2a derivatives and NC2b derivatives
were overproduced in transformants of E. coli strain
BL21(DE3) (Novagen, Inc.), and were puriﬁed under
denaturing conditions by metal-ion aﬃnity chromatogra-
phy on Ni
2+NTA-agarose [Qiagen, Inc.; pH-shift elution;
procedures per instructions of the manufacturer]. NC2
derivatives were reconstituted by addition of 3mg
(100nmol) NC2a derivative to 2mg (100nmol) NC2b
derivative in 100mM sodium phosphate, pH 4.5, 10mM
Tris–HCl and 8M urea; dilution of the sample to
0.5mg/ml with 100mM sodium phosphate, 10mM
Tris–HCl, pH 8.0 and 8M urea; stepwise dialysis, with
6–12h per step, against buﬀer E containing 2M urea,
against buﬀer E containing 0.5M urea and against
buﬀer E; concentration using a collodion membrane
(Schleicher & Schuell, Inc.; 25K MWCO); and further
puriﬁcation by gel ﬁltration on Superdex 200 HiLoad
16/60 (GE Healthcare, Inc.) pre-equilibrated with, and
eluted with, buﬀer D; and were stored in aliquots at
 808C.
TFIIB
Human TFIIB was prepared as in Ref. (26) (except that
the wash buﬀer in metal-ion aﬃnity chromatography con-
tained 45mM imidazole), desalted into buﬀer E on Bio-
Gel P-6DG (Bio-Rad, Inc.) and stored in aliquots
at  808C.
TFIIF
Human TFIIF was prepared as in Ref. (26), desalted into
buﬀer D on Bio-Gel P-6DG (BioRad, Inc.) and stored in
aliquots at  808C.
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Human RNAPII was prepared as in Ref. (26), dialyzed
against buﬀer E containing 10mM b-mercaptoethanol
and 40% glycerol and stored in aliquots at  808C.
Electrophoretic-mobility shift assays
Electrophoretic mobility shift assays were performed
as in Ref. (15), except that the DNA fragment was
AdMLP( 60/ 15).
Avidin–biotin-complex blotting
Proteins were separated by SDS–PAGE and were trans-
ferred to PVDF membranes (Immobilon-P; Millipore,
Inc.) in transfer buﬀer (25mM Tris base, 200mM glycine
and 20% methanol) for 1h at 48C at 100V in a Mini
Trans-Blot electrophoretic-transfer cell (Bio-Rad, Inc.).
Membranes were incubated for at least 10min at 228C
in PBS (5mM sodium phosphate, pH 7.2 and 150mM
NaCl) containing 0.2% Tween-20 (Pierce, Inc.) and then
were incubated for at least 1h at 228C in blocking solution
[PBS containing 6% casein (Tropix, Inc., Bedford, MA,
USA) and 0.1% Tween-20; prepared by gently stirring
PBS containing 6% casein for 1h at 658C, followed by
cooling to 228C, followed by addition of Tween-20;
stripped of contaminating of biotin and biotinylated pro-
teins by incubation for 16h at 48C with 0.01 volume of
avidin-agarose (Sigma, Inc.); ﬁltered through a sintered-
glass ﬁlter; and stored at  208C]. Blocked membranes
were washed for 10min at 228C with Avidin–biotin com-
plex (ABC) wash buﬀer (PBS containing 0.1% casein and
Tween-20), were incubated for 30min at 228C with gentle
agitation in Vecstain Elite ABC agent (Vector
Laboratories, Inc., Burlingame, CA, USA; prepared
during the blocking step by addition of 45ml Vecstain
Elite ABC agent A and 45ml Vecstain Elite ABC agent
B to 2.5ml ABC wash buﬀer and incubation for 30min
at 228C, followed by addition of 20ml blocking buﬀer at
228C), and were repeatedly washed with ABC wash buﬀer
at 228C (at least 10 changes of wash buﬀer over 3–4h).
Processed membranes were applied to SuperSignal West
Femto Maximum Sensitivity Substrate (Pierce, Inc.), incu-
bated for 3min at 228C, and placed in a development
folder (Tropix, Inc.) with BioMax ML ﬁlm (Kodak,
Inc., Rochester, NY, USA). Detection sensitivities were
quantiﬁed by performing dilution series with a prepara-
tion of biotinylated bovine serum albumin containing 13-
mol biotin per mole protein (Sigma, Inc.).
Ni
2+-NTA-conjugated horseradish peroxidase blotting
Ni
2+-NTA-conjugated horseradish peroxidase blotting
was performed using Ni-NTA-conjugated HRP (Qiagen,
Inc.; procedures per instructions of the manufacturer) and
SuperSignal West Femto Maximum Sensitivity Substrate
(Pierce, Inc.).
Photocrosslinking
Standard reaction mixtures contained (50ml): 30nM
[Thr176;(B-AE)Cys236]TBPc or [Thr176;(B-TEG-AE)
Cys236]TBPc and 150fmol DNA fragment AdMLP
( 50/ 16) immobilized on agarose beads [0.005ml
AdMLP( 50/ 16)-agarose containing 30pmol DNA per
milliliter agarose], in buﬀer F [20mM Tris–HCl, 20mM
HEPES–NaOH, pH 7.9, 60mM KCl, 10mM MgCl2,
8mM (NH4)2SO4, 0.05mM EDTA, 0.1mM phenyl-
methylsulfonyl ﬂuoride, 25 mg/ml poly(dG-dC) (GE
Healthcare, Inc; mean size, 700kDa), 24mg/ml polyethy-
lene glycol (mean size, 8kDa) and 5% glycerol]. For
experiments with the TFIIA–TBP–DNA complex,
TFIIA derivatives were added to standard reaction mix-
tures to a ﬁnal concentration of 200nM. For experiments
with the NC2–TBP–DNA complex, NC2 derivatives were
added to standard reaction mixtures to a ﬁnal concentra-
tion of 200nM. For experiments with the RNAPII–
TFIIF–TFIIB–TFIIA–TBP–DNA complex, RNAPII,
TFIIF, TFIIB, TFIIA and 2-mercaptoethanol were
added to standard reaction mixture to ﬁnal concentrations
of 100nM, 100nM, 60nM, 60nM and 1mM, respectively.
Reaction mixtures were incubated for 30min at 308C with
gentle agitation, and then were transferred to polystyrene
microcentrifuge tubes. Complexes immobilized on agarose
beads were collected by centrifugation (2000g; 2min at
228C), washed twice with 200ml of buﬀer UV-irradiated
for 20s at 350nm at 1 10
5erg mm
 2s
 2 in a Rayonet
RPR100 photochemical reactor (Southern New England
Ultraviolet, Inc., Branford, CT, USA).
Crosslink detection
Immediately following UV-irradiation, crosslink-
cleavage/label-transfer solution (30ml, 1.5M urea,
150mM sodium iodide and 150mM 2-mercaptoethanol)
was added, and samples were incubated for 15min at
228C. Samples were clariﬁed by centrifugation (2000g;
2min at 228C), transferred to new tubes, mixed with
SDS–PAGE loading buﬀer (27) and analyzed by SDS–
PAGE (precast gradient gels; Invitrogen, Inc.) followed
by ABC blotting.
Crosslink mapping
Large-scale crosslinking reactions for crosslink mapping
were performed as described above for standard crosslink-
ing reactions, except that the reaction volume was 1ml
and the reaction contained 10pmol DNA fragment
AdMLP( 50/ 16) immobilized on agarose beads
[0.01ml AdMLP( 50/ 16)-agarose containing 1nmol
DNA per milliliter agarose]. Following cross-link clea-
vage, label transfer and SDS–PAGE (performed as
described above for standard crosslinking reactions), gel
slices containing proteins of interest were excised, washed
four times with 1ml water and crushed using a microcen-
trifuge pestle. Proteins were eluted by incubation of
crushed gel slices in 3 volumes of 0.1% SDS and 5mM
2-mercaptoethanol for 12h at 228C with gentle agitation
and were precipitated by addition of ice-cold acetone
(28,29). Proteins were redissolved in 20ml 0.2M Tris–
HCl, pH 8.3, 0.1% SDS and 5mM tris(2-carboxyethyl-
phosphine)-hydrochloride (Pierce, Inc.); incubated for
15min at 658C; incubated for 15min at 378C; supplemen-
ted with 2ml 0.15M 2-nitro-5-thiocyanatobenzoic acid
(Aldrich, Inc.; dissolved in ethanol); incubated for
Nucleic Acids Research, 2008, Vol. 36, No. 19 6147Figure 1. Site-speciﬁc protein–protein photocrosslinking. (A) Strategy for identiﬁcation of protein(s) and amino acid(s) close to a single, deﬁned site
of interest within a multiprotein complex by use of photocrosslinking and label transfer (19,20). (i) Formation of a multiprotein complex having a
photoactivatible crosslinking agent incorporated at a single, deﬁned site of interest. The photoactivatible crosslinking agent contains a
detectable label (asterisk) and is attached to the site of interest through a disulﬁde linker (SS). (ii) Photocrosslinking. (iii) Cleavage and label
transfer. (B)
125I-AET [photocrosslinking agent of previous work; also known as
125I-PEAS; detectable label is
125I; (19,20)]. (C) B-AET
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to adjust pH to 9.0; and incubated for 16h at 378C with a
mineral oil overlay. Cleavage products were analyzed by
SDS–PAGE followed by ABC blotting.
RESULTS
Reagents and procedures for nonradioactive, ultrasensitive
site-specific protein–proteinphotocrosslinking
In previous work, we have developed reagents and pro-
cedures that enable identiﬁcation of protein(s) and
amino acid(s) close to a single, deﬁned site of interest
within a multiprotein complex by use of photocrosslinking
and label transfer (19,20). The approach entails three steps
(Figure 1A). In the ﬁrst step, one prepares a multiprotein
complex having a radiolabeled, cleavable photoactivatible
crosslinking agent incorporated at a single, deﬁned site of
interest (Figure 1A, top; Figure 1B). In the second step,
one photoirradiates the multiprotein complex initiating
crosslinking (Figure 1A, center). In the third step, one
cleaves the resulting crosslink(s), transferring radiolabel
to the protein(s) and amino acid(s) at which crosslinking
occurred, and one identiﬁes the radiolabeled protein(s)
and amino acid(s) (Figure 1A, bottom). The approach
has been applied to analysis of protein–protein interac-
tions within both bacterial transcription complexes
(19,30) and eukaryotic transcription complexes (31–35).
The approach is eﬀective. However, the approach requires
use of a radiolabel (
125I), and the approach has relatively
low detection sensitivity [ 2fmol; limited by the maxi-
mum speciﬁc activity of
125I (4.7dpm/fmol) and the mini-
mum activity of
125I required to produce a distinct band in
autoradiography ( 10dpm)].
In this work, we have developed reagents and proce-
dures that enable nonradioactive, ultrasensitive identiﬁca-
tion of protein(s) and amino acid(s) close to a single,
deﬁned site of interest within a multiprotein complex by
use of photocrosslinking and label transfer. The reagents
and procedures are analogous to those of our previous
work, except that the label is biotin (Figure 1B–D), the
method of label detection is ABC blotting (Figure S1) and
the formation, photoirradiation and processing of multi-
protein complexes are performed on DNA fragments
immobilized on agarose beads. Use of biotin as the label
enables nonradioactive reagents. Use of ABC blotting as
the method of label detection enables attamole-level detec-
tion sensitivity ( 2amol; representing a 1000-fold
improvement over our previous work; Figure S1). Use
of DNA fragments immobilized on agarose beads facili-
tates handling.
We have synthesized two biotin-labeled, cleavable
photoactivatible crosslinking agents: B-AET (III;
Figure 1C) and B-TEG-AET (VI; Figure 1D). The
azidosalicylamido moiety present in each agent permits
photocrosslinking. The 2-thiopyridyl moiety present in
each agent permits cysteine-speciﬁc incorporation into a
protein through a disulﬁde linkage—a linkage that can be
cleaved quantitatively by treatment with dithiothreitol or
2-mercaptoethanol (Figure 1C and D). Each agent can be
incorporated at a single, deﬁned site within a protein by a
two-step procedure consisting of: (i) site-directed muta-
genesis to introduce a unique surface cysteine residue at
the site of interest, followed by (ii) cysteine-speciﬁc chemi-
cal modiﬁcation. For each agent, in the resulting deriva-
tized protein, the length of the linker arm between the a
carbon of the cysteine residue and the photoreactive atom
is 14A ˚ (1.9 times the length of an arginine-side chain). The
length of the linker arm is suitable for analysis of interac-
tions occurring at, or just beyond, side-chain contact
distance.
Both B-AET and B-TEG-AET are compatible with
nonradioactive, ultrasensitive photocrosslinking and
label transfer (Figures 2 and 3). B-TEG-AET oﬀers
an important additional advantage that, in proteins
derivatized with this agent, the disulﬁde linkage between
protein and probe is resistant to cleavage by low to mod-
erate concentrations of 2-mercaptoethanol—presumably
because the triethyleneglycol (TEG) linker hinders access
by low to moderate concentrations of 2-mercaptothanol
(Figure S2). As a result, proteins derivatized with this
agent can be used in crosslinking reactions in the presence
of low to moderate concentrations of 2-mercaptoethanol,
and thus can be used in crosslinking reactions with multi-
protein complexes, such as human RNAPII transcription
initiation complexes (Y.K., D.R. and R.H.E., unpublished
data), that undergo oxidative damage in the absence of
reducing agents (Figure 3).
B-AET and B-TEG-AET bear similarities to biotin-
labeled, cleavable photoactivatible crosslinking agents
reported by Benkovic and co-workers (36–39) and
Outten and co-workers (40). However, the agents reported
by Benkovic and co-workers and Outten and
co-workers yield derivatized proteins with longer linker
arms between the a carbon of the cysteine residue and
the photoreactive atom (18A ˚ versus 14A ˚ for B-AET
and B-TEG-AET), rendering these agents less suitable
for analysis of interactions occurring at, or just beyond,
side-chain contact distance. In addition, to our knowl-
edge, these agents have not been demonstrated to enable
crosslinking with attamole-level detection sensitivity or to
enable crosslinking reactions in the presence of low to
moderate concentrations of 2-mercaptoethanol.
TBPderivatives fornonradioactive, ultrasensitive
site-specific protein–protein photocrosslinking
We prepared a human TBPc derivative containing no sol-
vent-accessible, reactive cysteine residues ([Thr176]TBPc,
(photocrosslinking agent of this work; detectable label is biotin). First line, synthesis. Second line, reaction with a protein having a unique surface
cysteine residue to yield a conjugate of form [S-(2-((N-biotinyl-2-aminoethyl)carbamoyl)-20-(4-azidosalicylamido)ethylthio)Cys]protein
([(B-AE)Cys]protein). In the resulting conjugate, the length of the linker arm between the a carbon of the cysteine residue and the photoreactive
atom is 14A ˚ .( D) B-TEG-AET (photocrosslinking agent of this work; detectable label is biotin). First line, synthesis. Second line, reaction with
a protein having a unique surface cysteine residue to yield a conjugate of form [S-(2-((N-biotinyl-11-amino-3,6,9-trioxaundecanyl)carbamoyl)-20-
(4-azidosalicylamido)ethylthio)Cys]protein ([(B-TEG-AE)Cys]protein). In the resulting conjugate, the length of the linker arm between the a carbon
of the cysteine residue and the photoreactive atom is 14A ˚ .
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unique solvent-accessible, reactive cysteine residue at posi-
tion 236 ([Thr176;Cys236]TBPc; Figure S3), a position
that is located within TBP H2 but that is not essential
for TFIIA–TBP or NC2-TBP interactions [(15); Y.K.,
D.R. and R.H.E., unpublished data]. [Wild-type human
TBPc contains a single solvent-accessible, reactive cysteine
residue: i.e. Cys176 (Figure S3). Substitution of Cys176
by Thr yields a TBPc derivative containing no solvent-
accessible, reactive cysteine residues (Figure S3), and
further substitution of Arg236 by Cys yields a TBPc
derivative having a single solvent-accessible, reactive
cysteine residue: i.e. Cys236 (Figure S3).] We reacted
[Thr176;Cys236]TBPc with B-AET, yielding a human
TBPc derivative containing a biotin-labeled, cleavable
photoactivatible crosslinking agent site-speciﬁcally
incorporated at position 236 within TBP H2 ([Thr176;
(B-AE)Cys236]TBPc; Figures 1D, S4 and S5). The eﬃ-
ciency of incorporation was  95% (as assessed spectro-
photometrically; Figure S4), and the site-speciﬁcity of
incorporation was  95% (as assessed spectrophotometri-
cally in parallel reactions with [Thr176]TBPc; Figure S4).
The resulting TBPc derivative was fully functional in for-
mation of TFIIA–TBP–DNA and NC2–TBP–DNA com-
plexes (Figure S5). In the resulting TBPc derivative, the
disulﬁde linkage between protein and probe was quantita-
tively cleaved by 2-mercaptoethanol at concentrations of
 0.8mM (reactions for 30min at 308C; Figure S2).
In the same manner, we reacted [Thr176;Cys236]TBPc
with B-TEG-AET, yielding a second biotin-labeled, cleav-
able photoactivatible crosslinking agent site-speciﬁcally
incorporated at position 236 within TBP H2 ([Thr176;
(B-TEG-AE)Cys236]TBPc; Figures 1D, S6, S7). The eﬃ-
ciency of incorporation was  95% (as assessed spectro-
photometrically; Figure S6), and the site speciﬁcity of
incorporation was  95% (as assessed spectrophotometri-
cally in parallel reactions with [Thr176]TBPc; Figure S6).
The resulting TBPc derivative was fully functional in
formation of TFIIA–TBP–DNA and RNAPII–TFIIF–
TFIIB–TFIIA–TBP–DNA complexes (Figure S7). In
the resulting TBPc derivative, the disulﬁde linkage
between protein and probe was quantitatively cleaved by
2-mercaptoethanol at concentrations of  10mM, but was
substantially resistant to cleavage by 2-mercaptoethanol at
a concentration of 1mM and was partly resistant to cleav-
age by 2-mercaptoethanol at a concentration of 5mM
(reactions for 30min at 308C; Figure S2).
Site-specific protein–protein photocrosslinking between
TBP H2and TFIIA: crosslinking within the
TFIIA–TBP–DNA complex
To assess interactions between human TFIIA and human
TBP H2 within the TFIIA-TBP–DNA complex in solu-
tion, we performed site-speciﬁc protein–protein photo-
crosslinking using [Thr176;(B-AE)Cys236]TBPc. The
results are presented in Figure 2. The results indicate
that crosslinking between TFIIA and TBP H2 occurs
and is eﬃcient (with an eﬃciency  20% of the eﬃciency
of intramolecular, self-crosslinking). The results further
indicate that crosslinking occurs exclusively with the
Figure 2. Site-speciﬁc protein–protein photocrosslinking between
TBP H2 and TFIIA: crosslinking within the TFIIA–TBP–DNA com-
plex. Biotin-labeled products of photocrosslinking followed by crosslink
cleavage and label transfer (ABC blot of SDS–polyacrylamide gel).
Lane 1, photocrosslinking reaction with TFIIA-[Thr176;(B-AE)
Cys236]TBPc–DNA complex; lane 2, control reaction omitting
UV-irradiation. Biotin-labeled TBPc is the product of intramolecular
self-crosslinking; biotin-labeled TFIIAa/b is the product of intermolec-
ular, TBPc ! TFIIAa/b, crosslinking. Control experiments in the
absence of DNA or in the absence of TFIIA show biotin-labeled
TBPc but do not show biotin-labeled TFIIAa/b.
Figure 3. Site-speciﬁc protein–protein photocrosslinking between
TBP H2 and TFIIA: crosslinking within the RNAPII–TFIIF–TFIIB–
TFIIA–TBP–DNA complex. Biotin-labeled products of photocrosslink-
ing followed by crosslink cleavage and label transfer (ABC blot
of SDS–polyacrylamide gel). Lane 1, photocrosslinking reaction with
RNAPII–TFIIF–TFIIB–TFIIA-[Thr176;(B-TEG-AE)Cys236]TBPc–
DNA complex; lane 2, photocrosslinking reaction with TFIIA-
[Thr176;(B-TEG-AE)Cys236]TBPc–DNA complex; lane 3, photocros-
slinking reaction with [Thr176;(B-TEG-AE)Cys236]TBPc–DNA
complex. Biotin-labeled TBPc is the product of intramolecular self-
crosslinking; biotin-labeled TFIIAa/b is the product of intermolecular,
TBPc ! TFIIAa/b, crosslinking. Control experiments in the absence of
DNA or in the absence of TFIIA show biotin-labeled TBPc but do not
show biotin-labeled TFIIAa/b.
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TFII g subunit). Control experiments establish that cross-
linking requires UV-irradiation, TFIIA and DNA. We
conclude that human TFIIAa/b is in direct physical proxi-
mity to human TBP H2 within the TFIIA–TBP–DNA
complex in solution.
Site-specific protein–protein photocrosslinking between
TBP H2and TFIIA: crosslinking within the
RNAPII–TFIIF–TFIIB–TFIIA–TBP–DNA complex
To determine whether interactions between human
TFIIAa/b and human TBP H2 also occur in a higher
order transcription–initiation complex, the RNAPII–
TFIIF–TFIIB–TFIIA–TBP–DNA complex,weperformed
site-speciﬁc protein–protein photocrosslinking using
[Thr176;(B-TEG-AE)Cys236]TBPc. [The disulﬁde linkage
between protein and probe in [Thr176;(B-AE)Cys236]
TBPciscleavedbylowtomoderateconcentrationsofredu-
cing agents (Figure S2); therefore, this TBPc derivative is
not suitable for crosslinking experiments involving human
RNAPII, which undergoes rapid oxidative damage and
rapid loss of activity, in the absence of reducing agents
(Y.K., D.R. and R.H.E., unpublished data). In contrast,
the disulﬁde linkage between protein and probe in
[Thr176;(B-TEG-AE)Cys236]TBPc is resistant to cleavage
by low to moderate concentrations of 2-mercaptoethanol
(presumably because the TEG linker hinders access by
2-mercaptoethanol; Figure S2); therefore, this TBPc deri-
vative is suitable for crosslinking experiments involving
human RNAPII.] The results are presented in Figure 3.
The results indicate that crosslinking between TFIIA and
TBP H2 occursand iseﬃcient (with an eﬃciency  20–30%
of the eﬃciency of intramolecular, self-crosslinking). The
results further indicate that crosslinking occurs essentially
exclusively with the TFIIA a/b subunit. There
is no signiﬁcant crosslinking to TFIIg, TFIIB, TFIIF sub-
units or to RNAPII subunits [all of which are electrophor-
etically well resolved from TFIIAa/b; see Ref. (26)].
Control experiments establish that crosslinking requires
UV-irradiation, TFIIA and DNA. Further control experi-
ments establish that, under the reaction conditions
used, [Thr176;(B-TEG-AE)Cys236]TBPc yields RNAPII–
TFIIF–TFIIB–TFIIA–TBP–DNA complexes and does
not yield TFIIA–TBP–DNA subcomplexes, implying
that the observed crosslinking arises from RNAPII–
TFIIF–TFIIB-TFIIA-TBP-DNA complexes and not
from TFIIA–TBP–DNA subcomplexes (Figure S7). We
conclude that TFIIAa/b is in direct physical proximity to
human TBP H2 within the RNAPII-TFIIF–TFIIB–
TFIIA–TBP–DNA complex in solution.
Site-specific protein–protein photocrosslinking between
TBP H2and TFIIA: mappingof crosslinks inTFIIAa/b
To deﬁne the site(s) on human TFIIAa/b at which cross-
linking occurs, we performed cysteine-speciﬁc proteolytic
mapping with 2-nitro-5-thiocyanatobenzoic acid (41).
We performed parallel reactions with wild-type TFIIA,
which contains a single cysteine residue at TFIIa/b posi-
tion 337, and with TFIIA derivatives—each veriﬁed to be
functional in formation of, and crosslinking within, the
TFIIA-TBP-DNA complex (Figure S8)—containing engi-
neered single cysteine residues at TFIIAa/b positions
61, 135, 214 and 280 (Figure 4A). [Wild-type human
TFIIAa/b contains a single cysteine residue: i.e. Cys337
(Figure 4A). Substitution of Cys337 by Ala yields a
TFIIAa/b derivative containing no cysteine residues
(Figure 4A), and further substitution of residues Ser61,
Ser135, Ser214 and Ser280 by Cys yields a set of four
TFIIAa/b derivatives each having a single cysteine resi-
due: i.e. Cys61, Cys135, Cys214 and Cys280 (Figure 4A).]
The results are presented in Figure 4B–C. The results indi-
cate that crosslinking occurs essentially exclusively within
residues 61–134 of TFIIAa/b. These residues are located
within the ‘connector’ segment of TFIIAa/b, between the
a-homologous and b-homologous segments of TFIIAa/b
(Figure 4A). They comprise the N-terminal third of the
‘connector’ segment of TFIIAa/b (Figure 4A). We con-
clude that the N-terminal third of the ‘connector’
segment of human TFIIAa/b is in direct physical proxi-
mity to human TBP H2 within the TFIIA–TBP–DNA
complex in solution.
Site-specific protein–proteinphotocrosslinking between
TBPH2 and NC2: crosslinking within the
NC2-TBP-DNA complex
To assess interactions between human NC2 and human
TBP H2 within the NC2-TBP-DNA complex in
solution, we performed site-speciﬁc protein–protein
photocrosslinking using [Thr176;(B-AE)Cys236]TBPc.
The results are presented in Figure 5. The results indicate
that crosslinking between NC2 and TBP H2 occurs and is
eﬃcient (with an eﬃciency  10% of the eﬃciency of intra-
molecular, self-crosslinking). The results further indicate
that crosslinking occurs exclusively with the NC2 a sub-
unit (with no detectable crosslinking to the NC2 b
Figure 4. Site-speciﬁc protein–protein photocrosslinking between TBP
H2 and TFIIA: mapping of crosslinks in TFIIAa/b.( A) Positions of
Cys residues in engineered single-Cys TFIIAa/b derivatives. The
TFIIAa domain and TFIIAb domain are indicated by shading; a-helices
and b-strands are numbered. (B) Products of Cys-speciﬁc cleavage of
engineered single-Cys TFIIAa/b derivatives (silver-stained SDS–polya-
crylamide gel). Product identities are based on results of blotting with
Ni
2+-NTA-conjugated horseradish peroxidase, which detects products
containing the heptahistidine sequence at TFIIAa/b positions 81–87
(Figure S9). (C) Biotin-labeled products of formation of TFIIA-
[Thr176;(B-AE)Cys236]TBPc–DNA complex with engineered single-Cys
TFIIAa/b derivatives, photocrosslinking, crosslink cleavage, label trans-
fer and Cys-speciﬁc cleavage (ABC blot of SDS–polyacrylamide gel).
Nucleic Acids Research, 2008, Vol. 36, No. 19 6151subunit). Control experiments establish that crosslinking
requires UV-irradiation, NC2 and DNA. We conclude
that human NC2a is in direct physical proximity to
human TBP H2 within the NC2-TBP-DNA complex in
solution.
Site-specific protein–proteinphotocrosslinking between
TBPH2 and NC2: mappingof crosslinks in NC2a
To deﬁne the site(s) on human NC2a at which crosslink-
ing occurs, we performed cysteine-speciﬁc proteolytic
mapping with 2-nitro-5-thiocyanatobenzoic acid (41).
We performed reactions with an NC2 derivative—veriﬁed
to be functional in formation of, and crosslinking within,
the NC2-TBP-DNA complex (Figure S10)—containing an
engineered single cysteine residue at position 73. [Wild-
type human NC2a contains two cysteine residues: i.e.
Cys54 and Cys73; substitution of Cys54 by Ser yields an
NC2a derivative containing a single cysteine residue: i.e.
Cys73 (Figure 6A).] This position is located at the bound-
ary between the N-terminal histone-fold domain of NC2a
and the C-terminal ‘tail’ of NC2a (Figure 6A). The results
are presented in Figure 6B and C. The results indicate that
crosslinking occurs essentially exclusively within the seg-
ment containing residues 73–205 of NC2a, and thus that
crosslinking occurs essentially exclusively within the seg-
ment corresponding to the C-terminal ‘tail’ of NC2a.W e
conclude that the C-terminal ‘tail’ segment of human
NC2a is in direct physical proximity to human TBP H2
within the NC2-TBP-DNA complex in solution.
DISCUSSION
Nonradioactive, ultrasensitive site-specific protein–protein
photocrosslinking
We have extended our previous approach for site-speciﬁc
protein–protein photocrosslinking (19,20) by providing
reagents and procedures for nonradioactive, ultrasensitive
site-speciﬁc protein–protein photocrosslinking (Figures 1,
S1). The reagents and procedures permit a detection sen-
sitivity of  2amol (a 1000-fold improvement in detection
sensitivity over our previous work), enabling application
of the approach to multiprotein complexes, such as human
RNAPII-containing transcription complexes, that are dif-
ﬁcult to prepare in large quantities. One of the reagents,
B-TEG-AET, permits crosslinking in the presence of
2-mercaptoethanol at concentrations up to  5mM
(Figure S2), enabling application of the approach to mul-
tiprotein complexes, such as human RNAPII-containing
transcription complexes, that are unstable in the absence
of reducing agents. The reagents and procedures are gen-
eralizable. In this work, we have applied the reagents
and procedures to analysis of TFIIA-TBP interactions
in the human TFIIA–TBP–DNA and RNAPII–TFIIF–
TFIIB–TFIIA–TBP–DNA complexes and to analysis of
NC2-TBP interactions in the human NC2–TBP–DNA
complex (Figures 2–6). In other work, we have applied
the reagents and procedures to analysis of TFIIB–TBP
interactions in the human TFIIB–TBP–DNA, RNAPII–
TFIIF–TFIIB–TBP–DNA and RNAPII–TFIIF–TFIIB–
TFIIA–TBP–DNA complexes (Y.K., Y.W.E, D.R. and
R.H.E., unpublished data). In still other work, we
Figure 5. Site-speciﬁc protein–protein photocrosslinking between TBP
H2 and NC2: crosslinking within the NC2–TBP–DNA complex. Biotin-
labeled products of photocrosslinking followed by crosslink cleavage
and label transfer (ABC blot of SDS–polyacrylamide gel). Lane 1,
photocrosslinking reaction with NC2–[Thr176;(B-AE)Cys236]TBPc–
DNA complex; lane 2, control reaction omitting UV-irradiation.
Biotin-labeled TBPc is the product of intramolecular self-crosslinking;
biotin-labeled NC2a is the product of intermolecular, TBPc ! NC2a,
crosslinking. Control experiments in the absence of DNA or in the
absence of NC2 show biotin-labeled TBPc but do not show biotin-
labeled NC2a.
Figure 6. Site-speciﬁc protein–protein photocrosslinking between TBP
H2 and NC2: mapping of crosslinks in NC2a.( A) Position of the
Cys residue in the engineered single-Cys NC2a derivative. Histone-
fold domains are indicated by shading; a-helices are numbered.
(B) Products of Cys-speciﬁc cleavage of the engineered single-Cys
NC2a derivative (silver-stained SDS–polyacrylamide gel). (C) Biotin-
labeled products of formation of NC2–[Thr176;(B-AE)Cys236]TBPc–
DNA complex with the engineered single-Cys NC2a derivative, photo-
crosslinking, crosslink cleavage, label transfer and Cys-speciﬁc cleavage
(ABC blot of SDS–polyacrylamide gel).
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kinetic analysis of CAP-RNAP interactions in bacterial
CAP–RNAP-DNA complexes (Druzhinin, S., Y.K.,
Y.W.E. and R.H.E., unpublished data).
TFIIA–TBP interaction: theTFIIAa/b‘connector’
interacts withTBP H2
Our results indicate that the ‘connector’ segment of
human TFIIA a/b subunit is in direct physical proximity
to H2 of human TBP in the TFIIA–TBP–DNA complex
in solution and in the RNAPII–TFIIF–TFIIB–TFIIA–
TBP–DNA complex in solution. The contact or close
approach involves amino acids 61–134 of human
TFIIAa/b subunit, which correspond to, but do not
show obvious amino acid sequence similarity to, amino
acids 57–131 of yeast TFIIA TOA1 subunit.
A contact or close approach between residues 61–134 of
the TFIIAa/b connector and TBP H2 was not observed
in published crystal structures of TFIIA–TBP–DNA com-
plexes, since most (in one crystal structure), or all (in three
crystal structures), of these residues were omitted from the
truncated TFIIA derivatives used in crystallization (8–10).
Nevertheless, a contact or close approach between these
residues of the TFIIAa/b connector and TBP H2 would be
compatible with published crystal structures of TFIIA–
TBP–DNA complexes, based on the locations of residues
preceding and following the connector, and on the acces-
sibility and location of TBP H2 (which is prominently
exposed on the face of TBP closest to TFIIA).
We propose that residues 61–134 of the human
TFIIAa/b connector make functional interactions with
TBP H2—interacting directly with TBP H2 and/or but-
tressing and positioning residues that interact directly with
TBP H2—and we propose that these functional interac-
tions account for genetic and NMR-spectroscopic evi-
dence suggesting involvement of TBP H2 in TFIIA–TBP
interaction (12–17).
NC2–TBP interaction: the NC2aC-terminal ‘tail’
interacts withTBP H2
Our results indicate that the C-terminal ‘tail’ of human
NC2a subunit—the segment of NC2a following the his-
tone-fold core domain of NC2a—is in direct physical
proximity to H2 of human TBP in the NC2-TBP-DNA
complex in solution. The contact or close approach
involves amino acids 73–205 of human NC2a subunit,
which correspond to, and which contain a segment with
obvious amino acid sequence similarity to, amino acids
114–142 of yeast NC2a subunit.
A contact or close approach between residues the NC2a
C-terminal tail and TBP H2 was not observed in the pub-
lished crystal structure of a NC2–TBP–DNA complex,
since the C-terminal tail was omitted, essentially in its
entirety, from the truncated NC2a derivative used in crys-
tallization (7). Nevertheless, a contact or close approach
between the NC2a C-terminal tail and TBP H2 would be
compatible with the published crystal structure, based on
the accessibility and location of the C-terminal residue of
the truncated NC2a derivative (which is prominently
exposed on the face of NC2 closest to TBP H2) and on
the accessibility and location of TBP H2 (which is promi-
nently exposed on the face of TBP closest to NC2a).
We propose that the human NC2a C-terminal tail
makes direct, functional interactions with TBP H2, and
we propose that these direct, functional interactions
account for genetic evidence suggesting involvement of
the NC2a C-terminal tail in NC2–TBP interaction and
NC2-dependent transcriptional repression (42,43) and
for genetic evidence suggesting involvement of TBP H2
in NC2–TBP interaction (18).
NC2–TFIIAcompetition
Comparison of published crystal structures of NC2–TBP–
DNA and TFIIA–TBP–DNA complexes does not provide
an obvious structural basis for competition between NC2
and TFIIA for interactions with the TBP–DNA complex
(7–10). There is minimal overlap, and minimal steric
incompatibility, between positions of residues of NC2
and TFIIA that interact with TBP, and there is no over-
lap, and no steric incompatibility, between residues of
NC2 and TFIIA that interact with DNA.
Our ﬁnding that the TFIIA and NC2—segments that
had been omitted from the truncated TFIIA and NC2
derivatives used in crystallization—interact with H2 of
TBP provides a simple structural basis for competition
between NC2 and TFIIA. Our ﬁndings suggest that com-
petition between NC2 and TFIIA involves overlap, and
steric incompatibility, between positions of residues of the
NC2a C-terminal tail that interact with TBP H2 and posi-
tions of residues of the TFIIAa/b connector that interact
with TBP H2.
Previous results indicate that NC2b subunit functions in
repression by using a C-terminal tail to interact with, and
to mask, a surface of TBP that alternatively interacts with
the general transcription factor TFIIB (7). Here, we pro-
pose that NC2a subunit functions in repression through
an analogous mechanism: using a C-terminal tail to inter-
act with, and to mask, a surface of TBP that alternatively
interacts with the general transcription factor TFIIA.
Thus, we propose that NC2 employs two analogous, but
independent, mechanisms to target TBP, each mediated by
the C-terminal tail of an NC2 subunit.
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